Growth and Launch Product Portfolio Success
Takeda's Growth and Launch Product portfolio grew by 14.7%, now accounting for 48% of total core revenue. Products like TAKHZYRO, FRUZAQLA, and ADZYNMA exceeded revenue expectations.
R&D Pipeline Progress
Significant progress in the late-stage pipeline with 6 Phase III programs underway. Notable achievements include positive Phase III data for rusfertide in polycythemia vera and completion of Phase III enrollment for zasocitinib in psoriasis and oveporexton in narcolepsy type 1.
Operational Efficiency and Profit Margin Growth
Core operating profit margin reached 25.4%, more than 2 percentage points above original expectations, driven by significant OpEx savings from efficiency programs.
Strong Free Cash Flow
Free cash flow was JPY 769 billion, exceeding forecasts due to lower CapEx and cash taxes, comfortably covering dividends and interest payments.
Dividend Increase
Takeda announced a further dividend increase to JPY 200 per share, in line with its progressive dividend policy.